Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life

CONCLUSIONS: RR-DTC with good performance status and RAI-avid disease obtain the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.PMID:38501238 | DOI:10.1210/clinem/dgae181

Source: The Journal of Clinical Endocrinology and Metabolism - March 19, 2024 Category: Endocrinology Authors: Vincenzo Marotta Domenico Rocco Anna Crocco Maria Grazia Deiana Ruggero Martinelli Francesca Di Gennaro Mariafelicia Valeriani Luca Valvano Alessia Caleo Luciano Pezzullo Antongiulio Faggiano Mario Vitale Salvatore Monti Source Type: research